Sleep Cycle AB (publ)

OM:SLEEP Rapport sur les actions

Capitalisation boursière : SEK 316.3m

Sleep Cycle Croissance future

Future contrôle des critères 4/6

Sleep Cycle devrait augmenter ses bénéfices et son chiffre d'affaires de 13.3% et de 10% par an respectivement. Le BPA devrait croître de diminuer de 19.7% par an. Le rendement des capitaux propres devrait être 28.2% dans 3 ans.

Informations clés

13.3%

Taux de croissance des bénéfices

-19.71%

Taux de croissance du BPA

Software croissance des bénéfices35.2%
Taux de croissance des recettes10.0%
Rendement futur des capitaux propres28.17%
Couverture par les analystes

Low

Dernière mise à jour30 Apr 2026

Mises à jour récentes de la croissance future

Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

May 02
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

Apr 30
Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

Recent updates

Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

May 02
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

SLEEP: Respiratory Research And Apnea Launch Will Support 2027 Margin Recovery

Analysts keep their SEK35.0 price target for Sleep Cycle unchanged, citing offsetting shifts in key model inputs such as slightly lower revenue growth assumptions, a reduced profit margin outlook, a marginally lower discount rate and a higher future P/E multiple. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping its premium features bundled into Revolut’s Premium, Metal and Ultra tiers and extending reach to Revolut’s global user base (Client Announcements).

SLEEP: Respiratory Disease Research Collaboration Will Drive Long Term Upside Potential

Analysts now see Sleep Cycle's fair value at SEK 30.75, down from SEK 39.50, reflecting updated views on revenue growth, profit margins and an outlook that applies a higher discount rate along with a much higher future P/E assumption. What's in the News Sleep Cycle introduced an AI-powered Sleep Score that focuses on duration, quality and routine.

SLEEP: Respiratory Research Collaborations Will Support 2027 Margin Recovery Upside

Analysts have maintained their SEK 35.00 price target on Sleep Cycle, with only small tweaks to assumptions around discount rate, revenue, profit margin and future P/E, reflecting a broadly steady outlook on the shares. What's in the News Sleep Cycle began a five-year research collaboration with The Delphi Group at Carnegie Mellon University, providing deidentified sleep-based cough and breathing data to support research on respiratory disease surveillance and early detection of seasonal and emerging outbreaks, including influenza, RSV and SARS-CoV-2.

SLEEP: Research Partnerships And 2027 Margin Recovery Will Drive Long Term Upside

Analysts are keeping their SEK price target for Sleep Cycle unchanged. A fair value of SEK 35.00 is maintained, as small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions effectively offset one another.

SLEEP: Licensing Deals And 2027 Margin Recovery Will Drive Long Term Upside

Analysts have reduced their Sleep Cycle fair value estimate from SEK 43.0 to SEK 35.0, reflecting a higher discount rate, a lower assumed future P/E, and slightly softer margin expectations, partly offset by a higher projected revenue growth rate. What's in the News Sleep Cycle issued earnings guidance indicating an EBIT margin of about 5% for 2026, linked to increased forward-looking investments.

These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts

Feb 09
These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts

Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53

Feb 07
Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53

SLEEP: Data Partnerships Will Drive Future Upside For This Undervalued Play

Analysts have lifted their price target for Sleep Cycle from $26.00 to $34.50, citing updated assumptions that combine a lower discount rate and higher projected profit margin with a different revenue growth outlook and a higher future P/E multiple. What's in the News Sleep Cycle and the UK Health Security Agency began a 12 week research collaboration to test whether anonymised, privacy preserved data from the Sleep Cycle app and its Cough Radar tool can support respiratory disease surveillance and early detection of patterns for viruses such as influenza, RSV and Covid 19 (Key Developments).

SLEEP: Expanding Licensing And AI Coaching Will Drive Long Term Upside

Analysts have maintained their fair value estimate for Sleep Cycle at $43.00. They cite more cautious assumptions on revenue growth and profit margins, together with a higher future P/E outlook, as key factors behind the unchanged target.

SLEEP: Expanding Licensing And AI Sleep Coaching Will Support Long Term Upside

Analysts have kept their fair value estimate for Sleep Cycle steady at US$43.00, pointing to only small tweaks in the discount rate, expected revenue growth and profit margin, along with a slightly lower future P/E assumption as the basis for the unchanged target. What's in the News Sleep Cycle signed a multi year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to integrate the company’s audio based sleep tracking analysis into its devices and broadening Sleep Cycle’s technology licensing activity (Key Developments).

There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings

Jan 04
There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings

SLEEP: Long Term Profit Margins Will Drive Stronger Future Upside Potential

Analysts have trimmed their price target on Sleep Cycle from approximately $49.00 to $43.00. This reflects expectations for slower revenue growth, partially offset by higher long term profit margins and a lower future price to earnings multiple.

Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%

Sep 09
Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%

Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.

Aug 27
Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.

Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model

Q2 2025 Update (updated 250823) Subscriptions continue to decline (-3%), leading to a top-line contraction that is likely to persist. However, partnerships are gaining momentum , with the company highlighting on the conference call that these could carry a more favorable margin profile.

Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities

Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75. What's in the News Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.

Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

Apr 30
Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%

Apr 29
The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%

Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00

Apr 08
Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00
User avatar

Medical-Grade Sleep Apnea Certification Will Open New Healthcare Partnerships

Exploring medical-grade certification and new revenue streams could enhance profitability, opening healthcare markets through partnerships and innovation.

Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's

Mar 06
Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's

Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year

Feb 10
Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year

Sleep Cycle's Revenue Set to Rise 10% with Strong Business Model

Company will continue its trajectory of 10% top line growth p.a. with possibility of more aggressive growth should new business materialize (e.g. data monetization or making the app medical device for

Prévisions de croissance des bénéfices et des revenus

OM:SLEEP - Estimations futures des analystes et données financières antérieures (SEK Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20282984746672
12/31/20272583848642
12/31/202621810-29162
3/31/2026236452243N/A
12/31/2025248534053N/A
9/30/2025257594959N/A
6/30/2025261625666N/A
3/31/2025263655562N/A
12/31/2024262636064N/A
9/30/2024256566063N/A
6/30/2024251556466N/A
3/31/2024243496569N/A
12/31/2023236464653N/A
9/30/2023229394050N/A
6/30/2023224333141N/A
3/31/2023218332737N/A
12/31/2022212345462N/A
9/30/2022206376470N/A
6/30/2022199346471N/A
3/31/2022191144955N/A
12/31/202118381420N/A
9/30/20211776813N/A
6/30/2021168121719N/A
3/31/2021163333536N/A
12/31/2020159444646N/A
12/31/201912342N/A48N/A
12/31/20189327N/A53N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de SLEEP ( 13.3% par an) est supérieure au taux d'épargne ( 2% ).

Bénéfices vs marché: Les bénéfices de SLEEP ( 13.3% par an) devraient croître plus rapidement que le marché Swedish ( 8.9% par an).

Croissance élevée des bénéfices: Les bénéfices de SLEEP devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de SLEEP ( 10% par an) devrait croître plus rapidement que le marché Swedish ( 0.1% par an).

Croissance élevée des revenus: Le chiffre d'affaires de SLEEP ( 10% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de SLEEP devrait être élevé dans 3 ans ( 28.2 %)

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/06 04:02
Cours de l'action en fin de journée2026/05/06 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Sleep Cycle AB (publ) est couverte par 4 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Oscar ErixonCarnegie Investment Bank AB
Erik GranströmDNB Carnegie
Rikard EngbergDNB Carnegie Commissioned Research